Core Viewpoint - Royalty Pharma plc has announced a $1.5 billion offering of senior unsecured notes, which will be used for general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of three tranches: $500 million of 5.150% Notes due 2029, $500 million of 5.400% Notes due 2034, and $500 million of 5.900% Notes due 2054 [1]. - The notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd, with the offering expected to close on June 10, 2024, subject to customary closing conditions [2]. Group 2: Underwriters and Managers - BofA Securities, Citigroup, J.P. Morgan, Morgan Stanley, and TD Securities are acting as joint lead bookrunning managers for the offering [3]. - Additional co-managers include DNB Markets, SMBC Nikko, SOCIETE GENERALE, US Bancorp, and several others [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry [6]. - The company collaborates with various entities, including academic institutions and leading global pharmaceutical companies, and has a portfolio that includes royalties on over 35 commercial products [6].

Core Viewpoint - Royalty Pharma has acquired a $905 million interest in Agios Pharmaceuticals' royalty on vorasidenib, contingent on FDA approval, which is expected to be a transformative therapy for IDH-mutant glioma patients [1][2][3]. Group 1: Acquisition Details - Royalty Pharma will pay Agios $905 million in upfront cash upon FDA approval of vorasidenib in exchange for a 15% royalty on annual U.S. net sales up to $1 billion and a 12% royalty on sales exceeding $1 billion [3]. - Agios will retain a 3% royalty on annual U.S. net sales greater than $1 billion [3]. Group 2: Product Information - Vorasidenib is an oral, selective dual inhibitor of IDH1/2 enzymes, targeting IDH-mutant diffuse glioma, with an estimated annual incidence of 1,500 patients and a prevalence of approximately 10,000 in the U.S. [2]. - The pivotal Phase 3 INDIGO clinical trial demonstrated significant efficacy and safety, meeting its primary endpoint of progression-free survival [2][8]. - Vorasidenib has received Breakthrough Therapy Designation from the FDA, with a PDUFA date set for August 20, 2024 [2][8]. Group 3: Financial Projections - Royalty Pharma projects peak annual sales for vorasidenib to exceed $1 billion, potentially generating over $150 million in annual royalties [4][8]. - If approved, royalties from vorasidenib are expected to continue through 2038 [4]. Group 4: Company Background - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [7]. - The company collaborates with various innovators, including academic institutions and biotechnology companies, to fund late-stage clinical trials and acquire existing royalties [7].

Core Insights - Vorasidenib, if approved, would be the first targeted therapy for IDH-mutant glioma, a progressive and incurable brain tumor [1][2] - The pivotal Phase 3 clinical study of vorasidenib showed unprecedented efficacy and tolerability, meeting its primary endpoint of progression-free survival [2][4] - Royalty Pharma has acquired an interest in Agios Pharmaceuticals' royalty on vorasidenib for $905 million, contingent on FDA approval [1][3] Financial Projections - Royalty Pharma projects peak annual sales for vorasidenib to exceed $1 billion in the U.S., with potential royalties exceeding $150 million annually [1][4] - Under the agreement, Royalty Pharma will pay Agios $905 million upfront upon FDA approval, receiving a 15% royalty on U.S. net sales up to $1 billion and a 12% royalty on sales exceeding that amount [3] Market Context - Vorasidenib targets IDH-mutant diffuse gliomas, which have an incidence of approximately 1,500 patients per year and a prevalence of around 10,000 in the U.S. [2] - The drug has received Breakthrough Therapy Designation from the FDA and is under priority review, with a PDUFA date set for August 20, 2024 [2][4]

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also ...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ET BofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also ...

Royalty Pharma PLC (NASDAQ:RPRX) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman & Chief Executive Officer Marshall Urist - Executive Vice President & Head, Research & Investments Chris Hite - Vice Chairman & Executive Vice President Terrance Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs ...

For the quarter ended March 2024, Royalty Pharma (RPRX) reported revenue of $717 million, down 36.6% over the same period last year. EPS came in at $0.98, compared to $1.60 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected that this company would post earnings of $1.03 per share when it actually produced earnings of $1.15, delivering a surprise of 11.65%.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Capital Deployment of approximately $670 million, including cash expected to be paid for frexalimab Development-stage portfolio growing to 15 therapies with potential significantly >$1 billion in peak royalties Financial guidance for full year 2024 (excludes contribution from future transactions) Exhibit 99.1 ROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 20 ...